Open AccessWhole-genome profiling of primary cutaneous anaplastic large cell lymphoma
Author(s) -
Armando N. Bastidas Torres,
Rutger C. Melchers,
Liana Van Grieken,
Jacoba J. Out-Luiting,
Hailiang Mei,
Cedrick Agaser,
Thomas B. Kuipers,
Koen D. Quint,
Rein Willemze,
Maarten H. Vermeer,
Cornelis P. Tensen
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2020.263251
Subject(s) - biology , transcriptome , cancer research , genetics , pten , pi3k/akt/mtor pathway , signal transduction , gene , gene expression
Primary cutaneous anaplastic large cell lymphoma (pcALCL), a hematological neoplasm caused by skin-homing CD30+ malignant T cells, is part of the spectrum of primary cutaneous CD30+ lymphoproliferative disorders. To date, only a small number of molecular alterations have been described in pcALCL, and so far, no clear unifying theme that could explain the pathogenetic origin of the disease has emerged among patients. To clarify the pathogenetic basis of pcALCL, we performed a high-resolution genetic profiling (genome/transcriptome) of this lymphoma (n=12) by using whole-genome sequencing, whole-exome sequencing and RNA sequencing. Our study, which uncovered novel genomic rearrangements, copy number alterations and small-scale mutations underlying this malignancy, revealed that the cell cycle, T-cell physiology regulation, transcription and signaling via the PI-3-K, MAPK and G-protein pathways are cellular processes commonly impacted by molecular alterations in patients with pcALCL. Recurrent events affecting cancer-associated genes included deletion of PRDM1 and TNFRSF14, gain of EZH2 and TNFRSF8, small-scale mutations in LRP1B, PDPK1 and PIK3R1 and rearrangements involving GPS2, LINC-PINT and TNK1. Consistent with the genomic data, transcriptome analysis uncovered upregulation of signal transduction routes associated with the PI-3-K, MAPK and G-protein pathways (e.g. ERK, phospholipase C, AKT). Our molecular findings suggest that inhibition of proliferation-promoting pathways altered in pcALCL (particularly PI-3-K/AKT signaling) should be explored as potential alternative therapy for patients with this lymphoma, especially, for cases that do not respond to first line skin-directed therapies or with extracutaneous disease.